NCT07299253 2025-12-23
Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06
Lanzhou University Second Hospital
Phase EARLY_PHASE1 Completed
Lanzhou University Second Hospital
Akeso
TransCode Therapeutics
Emory University
University of Michigan Rogel Cancer Center
Shanghai Pharmaceuticals Holding Co., Ltd
SmartNuclide Biopharma
ProgenaBiome
University of Zurich
Seoul National University Hospital
Abramson Cancer Center at Penn Medicine
Ohio State University Comprehensive Cancer Center
University of Chicago